FDA Approves Amgen's Vectibix
Drug Type: Vectibix is classified as a "monoclonal antibody" and "signal transduction inhibitor" by binding to epidermal growth factor receptors (EGFR). What Vectibix Is Used For: Vectibix is used to treat colorectal cancer that has spread.
It is used to treat colon cancers that express EGFR and disease that has gotten worse either on or following fluoropyrimidine, oxaliplatin and irinotecan containing chemotherapy regimens.
Vectibix is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human Epidermal Growth Factor Receptor (EGFR). Overexpression of EGFR is detected in many human cancers, including those of the colon and rectum. When Vectibix binds to EGFR it competitively inhibits the binding of ligands for EGFR. This results in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production.
Vectibix is specifically indicated for for the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
One more addition can now be made in the treatment of cancer with a new drug that can help cancer patients in getting treatment with an advanced stage of disease proving fatal for life.
The drug called ‘Vectibix’ which has been approved by Food and Drug Administration (FDA) meant for the patients with metastatic colon cancer, after testing its effectiveness in slowing the growth of tumor and in some cases sinking the size of tumor to be given by IV following standard chemotherapy treatments.
‘Vectibix’ is a monoclonal antibody that reacts with particular antigens on certain kind of cancer cells.
Vectibix treats colorectal cancer that's spread
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved Vectibix (panitumumab) following priority review. Vectibix is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy regimens.
The FDA approval of Vectibix was based on a progression-free survival endpoint. Vectibix is the first anti-EGFr antibody shown to significantly improve progression-free survival in patients with metastatic colorectal cancer. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix. Vectibix can be conveniently administered intravenously once every two weeks.